Skin + Me secures £10m in a Series B round led by Octopus Ventures to expand its personalised skincare platform.
Octopus Ventures led the Series B financing to support product innovation and marketing growth.
Skin + Me is a London-based skintech startup providing bespoke prescription treatments and skincare products tailored to individual medical histories.
London-based skintech startup Skin + Me has secured £10m in a Series B funding round led by Octopus Ventures. The company provides custom topical treatments formulated with prescription-only active ingredients and designed by consultant dermatologists.
The fresh capital will be directed towards accelerating growth through product innovations in personalised skincare and the development of new marketing channels.
Founded in 2020 at the height of the COVID-19 pandemic by James Mishreki and Horatio Cary, the firm addresses the shortage of dermatology services in the UK by offering direct-to-consumer custom formulations. Its product line includes the patented Daily Doser dispenser and a range of supplementary cleansers and moisturisers introduced in 2022.
From the founder
"Our mission was to create a game-changing, personalised skincare brand to democratise dermatology. I’ve now moved on to my next D2C venture and I’m delighted the team is doing such a good job delivering that vision to hundreds of thousands of people,"
James Mishreki
Founder at Skin + Me
Investor perspective
"Octopus Ventures takes pride in backing companies that incite positive and actionable change. Increased awareness of prescription ingredients and a growing trend towards personalisation have transformed the skincare market. Skin + Me lead the charge with its accelerated growth reflecting a step change that’s seen hyper-educated consumers shun off-the-shelf products in favour of highly efficacious solutions. Across Series A and Series B funding, Octopus Ventures has invested a total of £13m to develop Skin + Me — deepening the relationship, and demonstrating their faith in the brand’s market-leading personalisation strategy."
Will Gibbs
Partner, Health, Octopus
Use of funds
- 01Continue product development
- 02Accelerate go-to-market
